Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence.

Xiang YZ, Xiong H, Cui ZL, Jiang SB, Xia QH, Zhao Y, Li GB, Jin XB.

J Exp Clin Cancer Res. 2013 Feb 13;32:9. doi: 10.1186/1756-9966-32-9. Review.

2.

Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.

Bhindi B, Locke J, Alibhai SM, Kulkarni GS, Margel DS, Hamilton RJ, Finelli A, Trachtenberg J, Zlotta AR, Toi A, Hersey KM, Evans A, van der Kwast TH, Fleshner NE.

Eur Urol. 2015 Jan;67(1):64-70. doi: 10.1016/j.eururo.2014.01.040.

PMID:
24568896
3.

High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.

Murtola TJ, Kujala PM, Tammela TL.

Prostate. 2013 Jun;73(9):923-31. doi: 10.1002/pros.22638.

PMID:
23334943
4.

The association between metabolic syndrome and advanced prostate cancer in Chinese patients receiving radical prostatectomy.

Zhang GM, Zhu Y, Dong DH, Han CT, Gu CY, Gu WJ, Qin XJ, Sun LJ, Ye DW.

Asian J Androl. 2015 Sep-Oct;17(5):839-44. doi: 10.4103/1008-682X.148138.

5.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
6.
7.

Metabolic syndrome increases the risk of aggressive prostate cancer detection.

Morote J, Ropero J, Planas J, Bastarós JM, Delgado G, Placer J, Celma A, de Torres IM, Carles J, Reventós J, Doll A.

BJU Int. 2013 Jun;111(7):1031-6. doi: 10.1111/j.1464-410X.2012.11406.x.

8.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
9.

Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.

Chao C, Jacobsen SJ, Xu L, Wallner LP, Porter KR, Williams SG.

BJU Int. 2013 May;111(6):954-62. doi: 10.1111/j.1464-410X.2012.11639.x.

10.

Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.

Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR.

J Urol. 2003 Jan;169(1):157-63.

PMID:
12478126
11.

Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).

Russo AL, Chen MH, Aizer AA, Hattangadi JA, D'Amico AV.

BJU Int. 2012 Oct;110(7):973-9. doi: 10.1111/j.1464-410X.2012.11470.x.

12.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x.

13.

Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.

Huang JG, Pedersen J, Hong MK, Harewood LM, Peters J, Costello AJ, Hovens CM, Corcoran NM.

BJU Int. 2013 May;111(6):921-7. doi: 10.1111/j.1464-410X.2012.11665.x.

14.

Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW.

J Urol. 2006 Oct;176(4 Pt 1):1404-8.

PMID:
16952644
15.

Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis.

Cao Y, Ma J.

Cancer Prev Res (Phila). 2011 Apr;4(4):486-501. doi: 10.1158/1940-6207.CAPR-10-0229. Review.

16.

Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis.

Mass AY, Agalliu I, Laze J, Lepor H.

J Urol. 2012 Sep;188(3):786-91. doi: 10.1016/j.juro.2012.05.011.

PMID:
22818136
17.

The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.

Kositsawat J, Flanigan RC, Meydani M, Choi YK, Freeman VL.

J Urol. 2007 Dec;178(6):2391-6; discussion 2396.

PMID:
17936811
18.

Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy.

Blute ML, Bostwick DG, Bergstralh EJ, Slezak JM, Martin SK, Amling CL, Zincke H.

Urology. 1997 Nov;50(5):733-9.

PMID:
9372884
19.

Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies.

Scosyrev E, Tobis S, Donsky H, Wu G, Joseph J, Rashid H, Messing E.

BJU Int. 2013 Mar;111(3 Pt B):E71-7. doi: 10.1111/j.1464-410X.2012.11527.x. Review.

20.

Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.

Mitsuzuka K, Narita S, Koie T, Kaiho Y, Tsuchiya N, Yoneyama T, Kakoi N, Kawamura S, Tochigi T, Habuchi T, Ohyama C, Arai Y.

BJU Int. 2013 May;111(6):914-20. doi: 10.1111/j.1464-410X.2012.11658.x.

Items per page

Supplemental Content

Support Center